Ann: Chimeric receives US patent covering CLTX CAR technology, page-8

Just like building a house, brick by brick, step by step CHM are building a leading cell therapy company that will take on the world.
Europe patent covered last year, and the large US now. Notice the mention in the patent of the NK, in combination this could be huge, even though there is a long way to go. If this IP works, I believe that CHM will look at all types of combination therapy's with other big pharma's drugs that are already in the market.
We all know that many of these drugs are making billions, but there patents have only so many years to go. Hence an IP like CHM have as a combination and the patent can then be drawn out a lot longer and more money in the pockets of big pharma. So there interest in something like CHM have is a no brainer for them.
And after all this, the patients lives can be prolonged or even saved, and that's a wonderful thing if it happens.